Lung cancer vaccines and gene therapy.

David P Carbone, Kristen M Hege

Journal: Lung cancer (Amsterdam, Netherlands) 2003;41 Suppl 1():S103-13

PMID: 12867069

Full Text on Elsevier Science View on PubMed

Abstract

A number of cancer vaccine and gene therapy approaches are being evaluated in patients with lung cancer. Cancer vaccine strategies include GM-CSF gene-modified cancer cells, liposomal MUC1 peptide, anti-idiotype antibody targeting GD3, Mage-3 peptide, and mutant p53 pulsed dendritic cells among others. Preliminary human trials have demonstrated immune responses as well as tumor regression in late stage disease. The largest human gene therapy experience in lung cancer is with intratumoral gene replacement therapy, predominantly with p53, but such approaches are limited to locoregional disease control. Earlier stage gene therapy programs targeting the immune system or tumor vasculature hold promise as systemic therapies for treatment of advanced, disseminated disease.

Address: Cell Genesys, Inc., 500 Forbes Blvd., South San Francisco, CA 94080, USA. [email protected]

DOI: 10.1016/s0169-5002(03)00153-3